Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

TRex Bio Q3 2026 Results: Net Loss of $13.2M, Loss Widens

TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-13.2-7.9
Net income-13.2-7.9
EPS (diluted, $ a share)$-10.06$-7.58

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TRXB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

TRex Bio, Inc.: key numbers

Share price
$10.77Close, Nov 16
Market cap
$310M
Shares outstanding
28.79MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from TRex Bio, Inc.

All →
4:05 PM ET 8-K
Financial Results

TRex Bio Financial Results

TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.

Term
Q3 2026

“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”

Johnston Erwin, Chief Executive Officer of TRexBio

“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”

Johnston Erwin, Chief Executive Officer of TRexBio
4:34 PM ET Form 4
Insider Buying

TRex Bio Insider Alexandria Venture Investments LLC Buys $2.5M of Stock

Alexandria Venture Investments LLC bought 178,571 shares of TRex Bio, Inc. at $14.00 a share, worth $2.5M in total on Oct 13, 2026. Shares held after the trade: 1,346,501 (+15.3%).

Value
$2.5M
Shares
178,571
Price
$14.00
Holding change
+15.3%
Trade date
Oct 13, 2026
4:57 PM ET 8-K
Other 8-K Filing

TRex Bio Other 8-K Filing

TRex Bio, Inc. filed its fourth amended and restated certificate of incorporation and second amended and restated bylaws in connection with the closing of its initial public offering. The amendments authorize 225 million shares of common stock and 25 million shares of preferred stock while establishing new procedures for stockholder proposals and director nominations.

4:30 PM ET Form 4
Insider Buying

TRex Bio Insider Svlsf VI LLC Buys $1.3M of Stock

Svlsf VI LLC bought 92,857 shares of TRex Bio, Inc. at $14.00 a share, worth $1.3M in total on Oct 8, 2026. Shares held after the trade: 7,356 (+71.8%).

Value
$1.3M
Shares
92,857
Average price
$14.00
Holding change
+71.8%
Trade date
Oct 8, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.